| Literature DB >> 29091765 |
Aram S Modrek1, Danielle Golub1, Themasap Khan1, Devin Bready1, Jod Prado1, Christopher Bowman2, Jingjing Deng3, Guoan Zhang3, Pedro P Rocha2, Ramya Raviram2, Charalampos Lazaris4, James M Stafford5, Gary LeRoy5, Michael Kader1, Joravar Dhaliwal1, N Sumru Bayin6, Joshua D Frenster6, Jonathan Serrano2, Luis Chiriboga2, Rabaa Baitalmal2, Gouri Nanjangud7, Andrew S Chi8, John G Golfinos9, Jing Wang10, Matthias A Karajannis11, Richard A Bonneau12, Danny Reinberg13, Aristotelis Tsirigos4, David Zagzag14, Matija Snuderl15, Jane A Skok2, Thomas A Neubert3, Dimitris G Placantonakis16.
Abstract
Low-grade astrocytomas (LGAs) carry neomorphic mutations in isocitrate dehydrogenase (IDH) concurrently with P53 and ATRX loss. To model LGA formation, we introduced R132H IDH1, P53 shRNA, and ATRX shRNA into human neural stem cells (NSCs). These oncogenic hits blocked NSC differentiation, increased invasiveness in vivo, and led to a DNA methylation and transcriptional profile resembling IDH1 mutant human LGAs. The differentiation block was caused by transcriptional silencing of the transcription factor SOX2 secondary to disassociation of its promoter from a putative enhancer. This occurred because of reduced binding of the chromatin organizer CTCF to its DNA motifs and disrupted chromatin looping. Our human model of IDH mutant LGA formation implicates impaired NSC differentiation because of repression of SOX2 as an early driver of gliomagenesis.Entities:
Keywords: ATRX; CTCF; DNA methylation; IDH; P53; SOX2; astrocytoma; chromatin looping; low-grade glioma; neural stem cells
Mesh:
Substances:
Year: 2017 PMID: 29091765 PMCID: PMC5687844 DOI: 10.1016/j.celrep.2017.10.009
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423